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Abstract
Background: Nephrotoxicity is the major side effect that limits the dose of cisplatin that can be safely administered,
and it is a clinical problem in cancer patients who received cisplatin combination chemotherapy. Recent evidence has
demonstrated that patients with chronic kidney disease (CKD) have an increased risk of developing acute kidney injury
(AKI). The present study was conducted to evaluate the prevalence of CKD risk factors in patients who received cisplatin
and to assess the correlation between CKD risk factors and cisplatin-induced AKI.
Methods: We retrospectively analyzed 84 patients treated with cisplatin combination chemotherapy for thoracic
malignancies. AKI was defined as a decrease in the estimated glomerular filtration rate (eGFR) > 25 % from base
line, an increase in the serum creatinine (sCre) level of > 0.3 mg/dl or ≥ 1.5 times the baseline level.
Results: Eighty of the 84 patients (95.2 %) had at least one risk factor for CKD. All enrolled patients received cisplatin
with hydration, magnesium supplementation and mannitol. Cisplatin-induced AKI was observed in 18 patients (21.4 %).
Univariate analysis revealed that cardiac disease and use of non-steroidal anti-inflammatory drugs (NSAIDs) were
associated with cisplatin-induced nephrotoxicity (odds ratios [OR] 6 and 3.56, 95 % confidence intervals [CI] 1.21–29.87
and 1.11–11.39, p = 0.04 and p = 0.04, respectively). Multivariate analysis revealed that cisplatin nephrotoxicity occurred
significantly more often in patients with both risk factors (OR 13.64, 95 % CI 1.11–326.83, p = 0.04). Patients with more
risk factors for CKD tended to have a greater risk of developing cisplatin-induced AKI.
Conclusions: We should consider avoiding administration of cisplatin to patients with CKD risk factors, particularly
cardiac disease and NSAID use.
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Background
Cisplatin is one of the most commonly administered
agents in the treatment of cancer. Cisplatin-based chemo-
therapy has demonstrated survival benefits for patients
with resected early-stage non-small cell lung cancer
(NSCLC), advanced-stage NSCLC, small-cell lung cancer
(SCLC) and malignant pleural mesothelioma [1–4].
However, cisplatin can have severe side effects—in par-
ticular, cisplatin-induced nephrotoxicity, which is dose
dependent and is the major side effect that limits the
acceptable dose of cisplatin [5]. Impairment of renal
function has been shown to be a clinical problem in
25–35 % of patients treated with cisplatin [5]. There-
fore, it is important to identify the predictors of
cisplatin-induced nephrotoxicity and to avoid adminis-
trating cisplatin to patients with these risk factors.
Recent studies have reported several risk factors for
chronic kidney disease (CKD), including lifestyle-related
diseases, smoking, use of non-steroidal anti-inflammatory
drugs (NSAIDs), cardiac disease and cerebrovascular
disease [6]. Patients with risk factors for CKD may have a
higher incidence of cisplatin-induced nephrotoxicity.
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Indeed, acute kidney injury (AKI) is more frequently ob-
served in patients with CKD [7, 8]. Furthermore, recent
studies have reported that patients with lung cancer have
a higher incidence of comorbidities than do patients with
other cancers [9]. The aims of this study were to evaluate
the prevalence of CKD risk factors in thoracic malignancy
patients who received cisplatin and to elucidate the cor-
relation between nephrotoxicity due to cisplatin-based
chemotherapy in patients with CKD risk factors.
Methods
Patients
We retrospectively analyzed the data of consecutive pa-
tients who received cisplatin combination chemotherapy
for thoracic malignancies as the first-line chemotherapy
in our hospital between January 2006 and December
2012. All patients provided written informed consent. The
study was conducted in accordance with the Helsinki
Declaration of the World Medical Association. The proto-
col was approved by the institutional review board of
Niigata University.
Hydration and treatment methods
Patients received cisplatin combination chemotherapy
every 3–4 weeks for 4–6 cycles. As a common anti-
emetic premedication, granisetron (3 mg) or palonose-
tron (0.75 mg) was combined with dexamethasone
(9.9 mg) and dissolved in 100 ml of normal saline and
infused to the patient, and oral aprepitant (125 mg on
day1, 80 mg on days 2–3) was given before and after
chemotherapy. Cisplatin was administered in 250 mL of
normal saline solution over 2 h in combination with
other chemotherapeutic agents and 3000–3850 ml of
hydration. All patients received 40 mEq of magnesium
sulfate and 300 ml of mannitol to prevent nephrotoxicity
(Additional file 1: Figure S1).
Nephrotoxicity evaluation
The estimated glomerular filtration rate (eGFR) (mL/min/
1.73 m2) was calculated using the equation of the Japanese
Society of Nephrology: eGFR (mL/min/1.73 m2) = 194 x
serum creatinine (sCre)-1.094 × age-0.287 (×0.739 if female)
[10]. We calculated and recorded the eGFR at four time
points: before the administration of cisplatin combination
chemotherapy, the minimum value during chemotherapy,
4 weeks after the last administration of cisplatin and the
maximum value during the follow-up period (6 months
after the last administration of cisplatin). AKI was defined
as follows: a decrease in eGFR > 25 % of baseline, an
increase in sCre level of > 0.3 mg/dl or ≥ 1.5 times the
baseline level in reference to the RIFLE (risk, injury, failure,
loss, and end stage) criteria and the Common Terminology
Criteria for Adverse Events version 4.0 [11, 12].
Risk factors
To identify the risk factors potentially associated with
the occurrence of a cisplatin-induced nephrotoxicity, we
examined the relationship between AKI incidence and the
following 17 CKD risk factors: old age (≥70 years old),
proteinuria, hematuria, dyslipidemia, diabetes melli-
tus, hypertension, hyperuricemia, obesity (body mass
index ≥ 25), smoking, NSAID use, cerebrovascular
disease, cardiac disease, autoimmune disease, infec-
tious disease, urinary-tract stone and a history of acute
renal failure [13]. We also assessed the following po-
tential risk factors: hypoalbuminemia (serum albumin
level < 3.5 g/dL), Eastern Cooperative Oncology Group
performance status (PS ≥ 1), the number of CKD risk
factors, sex, Charlson Comorbidity Index (CCI) score,
and combined anticancer drugs [14–16].
Statistical analysis
The differences in the categorical variables between pa-
tients with and those without AKI were determined
using the chi-squire test or Fisher’s exact test, as appro-
priate. Two-sided P < 0.05 was considered statistically
significant. To identify the variables significantly associ-
ated with AKI, multivariate logistic regression analysis
was performed. All statistical analyses were performed




A total of 84 patients who were treated with cisplatin
combination chemotherapy for thoracic malignancies
were included in this study. The patient characteristics
are listed in Table 1. There were 19 (22.6 %) female pa-
tients and the median age of all the patients was 61 years
old (range, 33–75 years). Seventy-nine (94 %) patients
had a PS 0–1, 52 (61.9 %) had NSCLC and 19 (22.6 %) had
SCLC. The median cisplatin dosage was 80 mg/m2/day,
and the median number of cycles was 4 (range, 1–6). The
patients received various cisplatin combination drugs, in-
cluding vinorelbine in 26 (31 %), etoposide in 14 (16.7 %),
docetaxel in 12 (14.3 %), pemetrexed in 11 (13.1 %),
gemcitabine in 4 (4.8 %), S-1 in 4 (4.8 %), irinotecan in
2 (2.4 %), and others in 11 (13.1 %). The median CCI
was 6 (range, 2–10).
Incidence and outcome of AKI
Cisplatin-induced AKI was observed in 18 (21.4 %) of
the 84 enrolled patients (Additional file 2: Table S1). In
the AKI group and in the no AKI group, the median
eGFR before administration of cisplatin was 79.2
(range, 59.2–101) and 82.4 (range, 60–113) mL/min/
1.73 m2, respectively. Two patients had mild renal dys-
function before cisplatin administration (eGFR, 59.2
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and 59.6 mL/min/1.73 m2). Additional file 2: Table S1
shows the number of patients with risk factors for CKD
in the AKI group and the no AKI group. In both
groups, the most frequent risk factor was smoking
(77.8 % in the patients with AKI and 83.3 % in the pa-
tients without AKI). All 18 (100 %) of the patients with
AKI and 61 (92.4 %) of the patients without AKI had at
least one risk factor.
Figure 1 shows the changes in eGFR in the 18 patients
with AKI. During follow-up period (6 months after the
last administration of cisplatin), the eGFR in 5 patients
(27.8 %) recovered to baseline, the eGFR in 11 patients
(61.1 %) recovered to between 75 % and baseline, and
the eGFR in 2 patients (11.1 %) did not recover to 75 %
of baseline.
Risk factors for developing AKI
In the univariate analysis, we identified cardiac disease
(odds ratio [OR] 6, 95 % confidence interval [CI] 1.21–
29.87, p = 0.04) and NSAID use (OR 3.56, 95 % CI
1.11–11.39, p = 0.04) as significant predictors of AKI
(Table 2). The eGFR before treatment (p = 0.22), and
the other risk factors for CKD, such as PS ≥ 1 (p = 0.48),
hypoalbuminemia (p = 0.49), female sex (p = 0.56), CCI
score (p = 0.78), the type of anticancer drugs (p = 0.15–0.9)
and the number of treatment cycles (p = 0.74) were not sig-
nificantly associated with cisplatin-induced AKI. Next, we
included cardiac disease and NSAID use in the logistic re-
gression model with the addition of age and sex to assess
the contribution of each risk factor to cisplatin-induced
AKI. Although each of these factors was not a significant
predictor of cisplatin-induced AKI, we found that cardiac
disease and NSAID use had relatively higher odds ratios
(OR 5, 95 % CI 0.89–30.4 and OR 3.45, 95 % CI 0.97–
12.12, respectively; Table 3). Additionally, AKI occurred
significantly more often in patients who presented both
cardiac disease and NSAID use (OR 13.64, 95 % CI 1.11–
326.83, p = 0.04). The multivariate analyses also revealed
that the patients with more risk factors for CKD tended to
have an increased risk of developing cisplatin-induced AKI.
Discussion
Cisplatin is one of the most active cytotoxic agents in
treatment of thoracic malignancies. Cisplatin or carbo-
platin combination chemotherapy is recommended as
the first-line chemotherapy for patients with lung
cancer [17, 18]. Because cisplatin has more severe non-
hematological toxicity than carboplatin does, particu-
larly in terms of nephrotoxicity and gastrointestinal
toxicity, cisplatin is more poorly tolerated than carbo-
platin. Although cisplatin-based chemotherapy has
been reported to be superior to carboplatin-based
chemotherapy in non-squamous NSCLC patients, the
number of patients administered cisplatin-based chemo-
therapy was limited in clinical practice [2]. Recent
progress in antiemetic therapies has greatly reduced
cisplatin-induced gastrointestinal toxicity. We and other
investigators have reported that triple antiemetic therapy
with a 5-HT3 receptor antagonist, dexamethasone and
aprepitant ameliorates cisplatin-induced nausea and
vomiting [19, 20]. However, cisplatin-induced nephro-
toxicity remains an unsolved problem. Although previous
studies have reported less toxic methods for administrating
cisplatin, such as hydration with the supplementation of
magnesium and mannitol, cisplatin-induced nephrotoxicity
Table 1 Base line characteristics of all study patients (n = 84)
Parameter
Gender
Male 65 (77.3 %)
Female 19 (22.6 %)
Age (y)





Small cell carcinoma 19 (22.6 %)
Adenocarcinoma 37 (44 %)
Large-cell carcinoma 2 (2.4 %)
Squamous cell carcinoma 13 (15.5 %)
Malignant pleural mesothelioma 6 (7.1 %)
Thymic malignancy 2 (2.4 %)
Others 5 (6 %)
Cisplatin
Median dose (mg/m2/day) (range) 80 (40–80)
Median cycle (range) 4 (1–6)
Anticancer drugs
Vinorelbine 26 (31 %)
Etoposide 14 (16.7 %)
Docetaxel 12 (14.3 %)
Pemetrexed 11 (13.1 %)
Gemcitabine 4 (4.8 %)
S-1 4 (4.8 %)
Irinotecan 2 (2.4 %)
Others 11 (13.1 %)
Serum creatinine (mg/dl)
Median (range) 0.72 (0.50–0.99)
eGFR (mL/min/1.73 m2)
Median (range) 81.1 (59.2–113.0)
Charlson Comorbidity Index
Median (range) 6 (2–10)
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still occurs in 6–14 % of patients [21, 22]. Compatible with
these studies, the current study showed that the incidence
of AKI was 21.4 % (18/84), despite the administration of
hydration, magnesium supplementation and mannitol.
We need to develop more effective strategies to prevent
cisplatin-induced nephrotoxicity.
Previous studies demonstrated that old age, female
sex, current smoking, hyperuricemia, hypoalbuminemia,
diabetes mellitus, cardiovascular disease and NSAID
use are risk factors for cisplatin-induced nephrotoxicity
[15, 21, 23]. Because recent evidence has demonstrated
that CKD is a risk factor for AKI, we hypothesized that
patients with risk factors for CKD would also be at risk
for cisplatin-induced nephrotoxicity [7]. The present
study showed that comorbidities, including CKD risk
factors, were frequent in patients with thoracic malig-
nancies (Additional file 2: Table S1). Univariate analysis
demonstrated that cardiac disease and NSAID use were
statistically significant predictors of cisplatin-induced
nephrotoxicity (Table 2). Although multivariate analysis
revealed that no single factor was significantly associated
with cisplatin-induced AKI, AKI did occur significantly
more frequently in patients who had both cardiac disease
and NSAID use (Table 3). The risk factors for cardiac
disease, such as hypertension, diabetes mellitus, dyslip-
idemia and smoking, are also risk factors for CKD.
These factors cause atherosclerosis in the renal arteries
and induce chronic ischemic injury to the tubulointer-
stitium [24]. Because tubular cells are the major target
of cisplatin-induced nephrotoxicity, it is not surprising
that cardiac disease is associated with this complication
[25]. Nonselective cyclooxygenase (COX) inhibition by
NSAIDs decreases prostaglandin synthesis and induces
vasoconstriction and renal ischemia. Cisplatin has been
suggested to induce injury in the renal vasculature and
ischemic injury of the kidneys; thus these effects of
NSAIDs may exacerbate cisplatin-induced nephrotoxicity
[25]. In this study, the non-selective COX inhibitor loxo-
profen was prescribed to 13 of the 17 patients who had re-
ceived NSAIDs (76.8 %). Use of selective COX 2 inhibitors
may reduce the risk of cisplatin-induced nephrotoxicity.
Furthermore, our study showed that an increased number
of CKD risk factors may be related to a higher incidence
of cisplatin-induced AKI (Tables 2 and 3). Patients with-
out CKD risk factors did not develop cisplatin-induced
AKI. By contrast, patients with 5 or more CKD risk factors
had relatively higher odds ratio (OR 4.55, 95 % CI 0.73–
28.65; Table 3). We also investigated whether CCI score,
which is a method of classifying prognostic comorbidity,
correlated with the incidence of cisplatin-induced AKI,
but no association was found [16].
In previous studies, cisplatin-induced nephrotoxicity
has been assessed on the basis of the elevated sCre levels
[21, 26]. However, Launay-Vacher et al. analyzed data for
4684 cancer patients and found that elevated sCre levels
were less sensitive than was decreased Cre clearance for
detecting renal impairment [27]. In that study, renal
impairment was commonly found in cancer patients
(57.4 %), and 53.4 % required dose reduction due to
nephrotoxicity. The authors concluded that the use of
Fig. 1 Changes of estimated glomerular filtration rate (eGFR). The eGFR was measured at four time points; before the treatment, under treatment,
4 weeks after last cisplatin administration and during follow-up period (6 months after last cisplatin administration)
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nephrotoxic drugs should be avoided in cancer pa-
tients at high risk for AKI. Thus, we included de-
creased eGFR (estimated using the equation developed
by the Japanese Society of Nephrology) in our AKI cri-
teria [10]. The current study demonstrated that a de-
crease in the eGFR ≥ 25 % from the baseline level was
detected in 22.4 % (18/84) of the patients, although
only 9.5 % (8/84) exhibited elevated sCre levels
of > 0.3 mg/dl or ≥ 1.5 times baseline. These data suggest
that GFR should be included in assessment of
cisplatin-induced nephrotoxicity. Cisplatin causes cell
injury and death in the proximal and distal tubules.
Although the long-term effects of cisplatin on renal
function have not been fully elucidated, previous stud-
ies indicated that cisplatin treatment may lead to sub-
clinical but permanent reductions in GFR [28]. By
contrast, Moon et al. reported that the elevated sCre
levels recovered in 80.5 % of patients after cisplatin-
induced AKI [29]. In the present study, of the 18 pa-
tients who had cisplatin-induced AKI, the eGFR in 16
(88.9 %) recovered to more than 75 % of the baseline
level during the follow-up period. Cisplatin combination
chemotherapy has been recommended as the first-line
chemotherapy for lung cancer patients [17, 18]. Patients
who develop cisplatin-induced AKI may have a higher risk
of nephrotoxicity with subsequent chemotherapies. In-
deed, AKI is a well-defined risk factor for CKD, and
patients who develop AKI have a several-fold increased
risk of developing CKD [30]. Further investigation should
be carried out to evaluate whether subsequent chemother-
apies can be safely administered to patients who had expe-
rienced cisplatin AKI.
Conclusion
To our knowledge, this is the first study to assess the in-
cidence of cisplatin-induced nephrotoxicity in patients
with CKD risk factors. We identified cardiac disease and
NSAID use as risk factors for cisplatin-induced nephro-
toxicity. In addition, patients who had a higher number
of CKD risk factors tended to have an increased risk of
cisplatin-induced nephrotoxicity.
Availability of data and materials
The dataset supporting the conclusions of this article is
included within the Additional file 3: Dataset S1.
Table 2 Univariate analysis by chi-square test or Fisher’s exact test
Risk factor Odds ratio 95 % C.I. P-value
CKD risk factors
Smoking 0.7 0.19–2.53 0.59
Hypertension 2.3 0.79–6.66 0.12
Dyslipidemia 2.25 0.70–7.20 0.17
Use of NSAIDs 3.56 1.11–11.39 0.04
Obesity 0.51 0.10–2.50 0.4
Diabetes mellitus 0.91 0.17–4.70 0.91
Hyperuricemia 1.05 0.20–5.57 0.95
Urinary tract stone - 0.12
Age ≥70 0.5 0.06–4.31 0.52
Cardiac disease 6 1.21–29.87 0.04
Hematuria - 0.29
Cerebrovascular disease - 0.29
Autoimmune disease 4 0.52–30.61 0.15
Proteinuria - 0.6
Infectious disease - -
Past history of ARF - -
Pt. with CKD risk - 0.29
Pt. without CKD risk - 0.29
No. of CKD risk factors
≤2 1
3 1.54 0.39–5.96 0.72
4 1.5 0.34–6.7 0.69
≥5 5 0.85–29.39 0.09
Other risk factors
PS ≥1 0.68 0.23–2.01 0.48
Alb <3.5 g/dL 0.69 0.24–1.97 0.49
Female 1.43 0.44–4.69 0.56
Anticancer drugs
Vinorelbine 1 0.35–3.25 0.9
Etoposide 2.44 0.70–8.49 0.15
Docetaxel 0.7 0.14–3.53 0.66
Pemetrexed 0.33 0.04–2.76 0.29
Gemcitabine 3.94 0.51–30.14 0.16
S-1 3.94 0.51–30.14 0.16
AKI acute kidney injury, CKD chronic kidney disease, NSAID non-steroidal
anti-inflammatory drug, ARF acute renal failure, PS performance status,
C.I. confidential interval
Bold P-values are significant at the 0.05 level
Table 3 Multivariate logistic regression analysis adjusted for age
and sex
Parameter Odds ratio 95 % C.I. P-value
Age 1.01 0.95–1.08 0.74
Female 1.99 0.52–7.11 0.3
Cardiac disease 5 0.89–30.4 0.07
Use of NSAIDs 3.45 0.97–12.12 0.06
Cardiac disease and use of NSAIDs 13.64 1.11–326.83 0.04
No. of CKD risk factors
≥3 2.11 0.69–6.79 0.19
≥4 2.68 0.83–8.5 0.1
≥5 4.55 0.73–28.65 0.1
NSAID non-steroidal anti-inflammatory drug
Bold P-value is significant at the 0.05 level
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Additional files
Additional file 1: Figure S1. Chemotherapy hydration protocol used in
this study. Cisplatin and other anticancer drugs were administrated with
3850 ml of hydration, magnesium sulfate (40 mEq) and mannitol (300 ml).
(PPTX 79 kb)
Additional file 2: Table S1. The characteristics of the patients with or
without AKI. (XLSX 14 kb)
Additional file 3: Dataset S1. The characteristics of the patients.
(XLSX 28 kb)
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